NCT00560820View on ClinicalTrials.gov

Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
β-thalassemiaTransfusional Iron Overload
Interventions
DRUG

Deferasirox

30 mg/kg/day

Trial Locations (3)

10043

Novartis Investigative Site, Orbassano

16128

Novartis Investigative Site, Genova

09121

Novartis Investigative Site, Cagliari

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY